Provided by Tiger Trade Technology Pte. Ltd.

COMPASS Pathways plc

5.73
-0.1500-2.55%
Pre-market: 5.66-0.0700-1.22%08:02 EDT
Volume:2.66M
Turnover:15.15M
Market Cap:650.37M
PE:-2.09
High:5.83
Open:5.78
Low:5.57
Close:5.88
52wk High:8.90
52wk Low:2.25
Shares:113.50M
Float Shares:58.41M
Volume Ratio:1.19
T/O Rate:4.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7367
EPS(LYR):-2.2987
ROE:-205.81%
ROA:-38.43%
PB:17.30
PE(LYR):-2.49

Loading ...

RBC Capital Sticks to Their Buy Rating for COMPASS Pathways (CMPS)

TIPRANKS
·
Jan 08

Stifel Nicolaus Remains a Buy on COMPASS Pathways (CMPS)

TIPRANKS
·
Jan 08

Compass Pathways Says FDA Accepts Application for PTSD Treatment; Shares Up Pre-Bell

MT Newswires Live
·
Jan 07

Compass Pathways Plc - on Jan 5, Co Entered Third Amendment to Loan and Security Agreement With Hercules

THOMSON REUTERS
·
Jan 07

Compass Pathways Plc - Secures $150 Mln Loan Agreement - SEC Filing

THOMSON REUTERS
·
Jan 07

Compass Pathways unveils investor presentation highlighting COMP360 Phase 3 results in treatment-resistant depression

Reuters
·
Jan 07

Compass Pathways Expands Loan Facility With Hercules Capital to $150 Million

Reuters
·
Jan 07

Compass Pathways Announces FDA Acceptance of Ind Application for Ptsd and Hosts Webinar on Ptsd and Trd

THOMSON REUTERS
·
Jan 07

Compass Pathways Plc - to Be Launch-Ready for Comp360 for Trd by Year-End

THOMSON REUTERS
·
Jan 07

Compass Pathways Partners with Radial Health to Advance Psilocybin Treatment Delivery

Reuters
·
Jan 06

Compass Pathways Establishes Strategic Collaboration With Radial to Innovate Patient Experience and Inform Potential Delivery Model of Comp360

THOMSON REUTERS
·
Jan 06

A small company can now advance its psychedelic into Phase 3. Here's why that matters to other psychedelic biotechs.

Dow Jones
·
Jan 05

Compass Pathways Hosts Webinar on Commercial Preparations for TRD and PTSD Clinical Trials

Reuters
·
Dec 09, 2025

Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (Trd) and Clinical Trial Plans for Post-Traumatic Stress Disorder (Ptsd) on January 7, 2026, 10:00Am Et

THOMSON REUTERS
·
Dec 09, 2025

Compass Pathways to Join Evercore and Piper Sandler Healthcare Conferences

Reuters
·
Nov 20, 2025

Compass Pathways Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Nov 06, 2025

RBC Adjusts Price Target on COMPASS Pathways to $16 From $15, Maintains Outperform Rating

MT Newswires Live
·
Nov 05, 2025

Compass Pathways to Participate in Stifel 2025 Healthcare Conference

Reuters
·
Nov 05, 2025

Stock Track | Compass Pathways Plunges 5.28% After Reporting Larger-Than-Expected Q3 Loss

Stock Track
·
Nov 05, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers Health, Hertz Global, Metsera

Reuters
·
Nov 04, 2025